China National Accord Medicines Corporation Ltd.
Shenzhen Stock ExchangeTotal Valuation
China National Accord Medicines Corporation Ltd. carries a market capitalization of 12.66B, placing it among publicly traded companies globally. Its enterprise value stands at 7.98B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 12.66B |
| Enterprise Value | 7.98B |
Share Statistics
China National Accord Medicines Corporation Ltd. currently has 556.57M shares outstanding.
| Shares Outstanding | 556.57M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
China National Accord Medicines Corporation Ltd. trades at a trailing price-to-earnings ratio of 7.52. The price-to-sales ratio is 0.11, and the price-to-book ratio stands at 0.42.
| PE Ratio | 7.52 |
| PS Ratio | 0.11 |
| PB Ratio | 0.42 |
| P/TBV Ratio | 0.30 |
| P/FCF Ratio | 49.91 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, China National Accord Medicines Corporation Ltd. trades at an EV/EBITDA multiple of 5.83 and an EV/FCF ratio of 34.97. The EV/Sales ratio of 0.15 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 5.83 provides insight into valuation relative to core operating earnings.
| EV / Sales | 0.15 |
| EV / EBITDA | 5.83 |
| EV / EBIT | 5.83 |
| EV / FCF | 34.97 |
Financial Position
China National Accord Medicines Corporation Ltd. maintains a current ratio of 1.56, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 18.69, indicating elevated leverage, while an interest coverage ratio of 9.50 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.56 |
| Quick Ratio | 0.20 |
| Debt / Equity | 18.69 |
| Debt / EBITDA | 2.99 |
| Interest Coverage | 9.50 |
Financial Efficiency
China National Accord Medicines Corporation Ltd. posts a return on equity of 5.78 and a return on invested capital of 3.79.
| Return on Equity (ROE) | 5.78 |
| Return on Assets (ROA) | 1.62 |
| Return on Invested Capital (ROIC) | 3.79 |
| Return on Capital Employed (ROCE) | 4.26 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 5.91 |
Taxes
Over the trailing twelve months, China National Accord Medicines Corporation Ltd. has paid 268.98M in income taxes, reflecting an effective tax rate of 25.67.
| Income Tax | 268.98M |
| Effective Tax Rate | 25.67 |
Stock Price Statistics
China National Accord Medicines Corporation Ltd.'s stock has gained approximately 13.54962% over the past 52 weeks. The 50-day moving average sits at 12.39, while the 200-day moving average is 12.45.
| Beta (5Y) | N/A |
| 52-Week Price Change | 13.54962% |
| 50-Day Moving Average | 12.39 |
| 200-Day Moving Average | 12.45 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, China National Accord Medicines Corporation Ltd. generated 54.62B in revenue and converted that into 804.18M in net income, yielding earnings per share of 1.41. EBITDA reached 1.37B, while operating income came in at 1.37B.
| Revenue | 54.62B |
| Gross Profit | 5.87B |
| Operating Income | 1.37B |
| Pretax Income | 1.05B |
| Net Income | 804.18M |
| EBITDA | 1.37B |
| EBIT | 1.37B |
| Earnings Per Share (EPS) | 1.41 |
Balance Sheet
China National Accord Medicines Corporation Ltd. holds 5.18B in cash and equivalents against 4.10B in total debt, resulting in a net debt position of -2.66B. Total book value stands at 14.35B, with working capital of 14.41B providing operational flexibility.
| Cash & Cash Equivalents | 5.18B |
| Total Debt | 4.10B |
| Net Debt | -2.66B |
| Equity (Book Value) | 14.35B |
| Book Value Per Share | 25.96 |
| Working Capital | 14.41B |
Cash Flow
After subtracting -121.25M in capital expenditures, free cash flow totaled -121.25M - equivalent to -0.22 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -121.25M |
| Free Cash Flow | -121.25M |
| FCF Per Share | -0.22 |
Margins
China National Accord Medicines Corporation Ltd. operates with a gross margin of 10.76, reflecting its pricing power and cost economics. The operating margin of 2.51 and net profit margin of 1.47 provide insight into operational efficiency.
| Gross Margin | 10.76 |
| Operating Margin | 2.51 |
| Pretax Margin | 1.92 |
| Profit Margin | 1.47 |
| EBITDA Margin | 2.51 |
Dividends & Yields
The company's payout ratio of 44.30 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.60 |
| Dividend Yield | N/A |
| Payout Ratio | 44.30 |
| Shareholder Yield | 7.78 |
| FCF Yield | 2.00 |
Stock Splits
China National Accord Medicines Corporation Ltd.'s most recent stock split took place on June 26, 2026 with a 10:11 split ratio.
| Last Split Date | 6/26/2026 |
| Split Ratio | 10:11 |
Scores
China National Accord Medicines Corporation Ltd. posts an Altman Z-Score of 2.17, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.17 |